Kyverna Therapeutics (KYTX) Shares Outstanding (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Shares Outstanding data on file, last reported at $60.5 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 40.06% year-over-year to $60.5 million; the trailing twelve-month figure through Mar 2026 stood at $60.5 million (up 40.06% YoY), and the FY2025 full-year result was $60.4 million, up 39.74% from the prior year.
• Shares Outstanding for Q1 2026 stood at $60.5 million, roughly flat from $60.4 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $60.5 million in Q1 2026 and bottomed at $1.0 million in Q1 2023.
• The 4-year median for Shares Outstanding is $43.2 million (2024), against an average of $32.9 million.
• The widest annual swing landed in 2024, when Shares Outstanding soared 4139.67%; it then rose 0.23% in 2025.
• A 4-year view of Shares Outstanding shows it stood at $1.3 million in 2023, then soared by 3356.91% to $43.2 million in 2024, then soared by 39.74% to $60.4 million in 2025, then advanced by 0.24% to $60.5 million in 2026.
• The last three Shares Outstanding figures came in at $60.5 million (Q1 2026), $60.4 million (Q4 2025), and $43.8 million (Q3 2025), per Business Quant data.

Peer Comparison